Orphanet Journal of Rare Diseases (Jun 2024)

Whole genome sequencing of HER2-positive metastatic extramammary Paget’s disease: a case report

  • Boon Yee Lim,
  • Zexi Guo,
  • Jing Quan Lim,
  • Tun Kiat Ko,
  • Elizabeth Chun Yong Lee,
  • Bavani Kannan,
  • Jing Yi Lee,
  • Abner Herbert Lim,
  • Zhimei Li,
  • Cedric Chuan-Young Ng,
  • Inny Busmanis,
  • Jason Yongsheng Chan

DOI
https://doi.org/10.1186/s13023-024-03169-y
Journal volume & issue
Vol. 19, no. 1
pp. 1 – 14

Abstract

Read online

Abstract Background Extramammary Paget’s disease (EMPD) is a rare cancer that occurs within the epithelium of the skin, arising predominantly in areas with high apocrine gland concentration such as the vulva, scrotum, penis and perianal regions. Here, we aim to integrate clinicopathological data with genomic analysis of aggressive, rapidly-progressing de novo metastatic EMPD responding to HER2-directed treatment in combination with other agents, to attain a more comprehensive understanding of the disease landscape. Methods Immunohistochemical staining on the scrotal wall tumor and bone marrow metastasis demonstrated HER2 overexpression. Whole genome sequencing of the tumor and matched blood was performed. Results Notable copy number gains (log2FC > 0.9) on chromosomes 7 and 8 were detected (n = 81), with 92.6% of these unique genes specifically located on chromosome 8. Prominent cancer-associated genes include ZNF703, HOOK3, DDHD2, LSM1, NSD3, ADAM9, BRF2, KAT6A and FGFR1. Interestingly, ERBB2 gene did not exhibit high copy number gain (log2FC = 0.4) although 90% of tumor cells stained HER2-positive. Enrichment in pathways associated with transforming growth factor-beta (TGFβ) (FDR = 0.0376, Enrichment Ratio = 8.12) and fibroblast growth factor receptor (FGFR1) signaling (FDR = 0.0082, Enrichment Ratio = 2.3) was detected. Amplicon structure analysis revealed that this was a simple-linear amplification event. Conclusion Whole genome sequencing revealed the underlying copy number variation landscape in HER2-positive metastatic EMPD. The presence of alternative signalling pathways and genetic variants suggests potential interactions with HER2 signalling, which possibly contributed to the HER2 overexpression and observed response to HER2-directed therapy combined with other agents in a comprehensive treatment regimen.

Keywords